Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

(TM), a late-stage vaccine candidate for the treatment of advanced prostate cancer, was acquired as part of the partnership that was entered with the National Cancer Institute. Very promising data were reported, showing prolonged survival combined with a favourable safety profile. Phase III studies expected to be initiated in 2010. - MVA-BN(R) Anthrax, a new preclinical programme for an anthrax vaccine, is expected to enter clinical trials in 2010. - MVA-BN(R) HIV multiantigen, in development as prophylactic and therapeutic vaccine against HIV, initiated clinical Phase I/II trials. - The company's MVA-BN(R) based prostate cancer vaccine also entered clinical Phase I/II trials. - A milestone payment of USD 25 million was received after submission of important IMVAMUNE(R) data. - The data that were generated from a larger Phase II study with IMVAMUNE(R) was submitted to the US health authorities for evaluation whether they can potentially support the use of IMVAMUNE(R) in a declared emergency. - More than 2,400 subjects have now been vaccinated with IMVAMUNE(R) - The first IMVAMUNE(R) contracts outside USA were signed with Canada and an Asian country.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "2008 was a successful year for Bavarian Nordic where all our primary goals were achieved. We implemented a new strategy, and this has already borne fruit. Our increased focus on cancer therapies which through to the partnership with the NCI led to the acquisition of PROSTVAC(TM) has strengthened our pipeline and we feel very optimistic about our cancer vaccines in the future. At the end of the year, we submitted the important safety data for IMVAMUNE(R) to the US health authorities and are now awaiting just one approval in order to initiate the delivery of the 20 million doses under the RFP-3
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... The report "1,6-Hexanediol Market by Application and By ... the global market on the basis of its ... such as the key drivers, current trends and ... 81 Market Data Tables and 29 Figures spread ... Market by Application and by Geography - Trends ...
(Date:10/18/2014)... 2014 The Asia-Pacific hardware encryption display ... Asia-Pacific with analysis and forecast of revenue. This market ... to reach $51,362.6 million by 2018, at a CAGR ... the TOC of the Asia-Pacific hardware encryption market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/18/2014)... 18, 2014 The Asian Electronic Medical Record ... Asian with analysis and forecast of revenue. The electronic medical ... to $2,328.0 million by 2018, at a CAGR of 9.4% ... the Asian Electronic Medical Record (EMR) market, to get an ... glimpse of the segmentation of the market in the same ...
(Date:10/18/2014)... According to a new market research report ... Global Trends & Forecasts up till 2017”, hydraulic fracturing ... This value is expected to increase from $40 billion ... CAGR during the same period. North America is expected ... terms of hydraulic horse power supplied by the year ...
Breaking Biology Technology:1,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4
... WILMINGTON, N.C., Sept. 9 Wilmington Pharmaceuticals announced ... granted marketing approval for METOZOLV((TM)) ODT (metoclopramide HCl), an ... gastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmington has ... pharmaceutical company with a focus on gastrointestinal disorders. , ...
... , SAN DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. ... obesity, today announced that the Company will be speaking at two upcoming investor ... , Morgan Stanley Global Healthcare Unplugged Conference, ... Time, Location: Grand Hyatt Hotel, New York, ...
... , , , , ... SAN FRANCISCO, Sept. 9 Medivation, Inc. (Nasdaq: MDVN ) ... the following conferences: , , , The ... Eastern Time at the Millennium Broadway Hotel in New York , ...
Cached Biology Technology:Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 2Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 3Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet 4Medivation Announces Participation in Upcoming Conferences 2
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
(Date:10/14/2014)... how to produce enough food to feed the world ... Organization of the United Nations predicts that food production ... feed a growing global population, and plants are one ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly ... tap into our knowledge of how plants work to ...
(Date:10/14/2014)... – A team of scientists led by researchers ... and the University of Miami Miller School of ... key genetic pathway underlying bipolar (manic depressive) disorder, ... for treating bipolar affective disorder, as well as ... new findings, published online this week in Nature ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... research from Queen Margaret University, Edinburgh, shows that sugary ... gain, carbohydrate craving or adverse mood effects in overweight ... drinking. The study, ,Effects of sucrose drinks ... overweight women over 4 weeks, which was conducted by ...
... formidable marine predators, the marine mosasaur Platecarpus , lived in ... to have swum like an eel. That theory is debunked in ... . An international team of scientists have reconceived the animal,s morphology, ... Natural History Museum of Los Angeles County. The ...
... researchers are developing methods that can accurately assess the ... and spectra of a patient,s prostate gland. This may ... treatment and which are better served by "watchful waiting," ... patients with low-grade tumors. In a presentation next ...
Cached Biology News:Research shows sugary drinks do not cause weight gain 2Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster 2Rutgers researchers assess severity of prostate cancers using magnetic resonance imaging 2
... Bio-Rad Molecular Imager VersaDoc MP 4000 ... CCD based imaging system capable of ... methods, including fluorescence, chemiluminescence, densitometry, and ... illumination sources allow imaging of multiplexed ...
...
...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
Biology Products: